Terms: = Lung cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
2683 results:
1. Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway.
Zhong J; Hua Y; Zou S; Wang B
PLoS One; 2024; 19(5):e0299921. PubMed ID: 38814975
[TBL] [Abstract] [Full Text] [Related]
2. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Xie M; Vuko M; Rodriguez-Canales J; Zimmermann J; Schick M; O'Brien C; Paz-Ares L; Goldman JW; Garassino MC; Gay CM; Heymach JV; Jiang H; Barrett JC; Stewart RA; Lai Z; Byers LA; Rudin CM; Shrestha Y
Mol Cancer; 2024 May; 23(1):115. PubMed ID: 38811992
[TBL] [Abstract] [Full Text] [Related]
3. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract] [Full Text] [Related]
4. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
[TBL] [Abstract] [Full Text] [Related]
5. A Comparative Analysis of Implant-sparing Plan
Onal C; Bozca R; Dolek Y; Elmali A; Guler OC
In Vivo; 2024; 38(3):1412-1420. PubMed ID: 38688603
[TBL] [Abstract] [Full Text] [Related]
6. Microwave ablation combined with percutaneous vertebroplasty for treating painful non-small cell lung cancer with spinal metastases under real-time temperature monitoring.
Wu L; Hu M; Li P; Man Q; Yuan Q; Zhang X; Qiu Y; Chen L; Fan J; Zhang K
J Cancer Res Ther; 2024 Apr; 20(2):540-546. PubMed ID: 38687923
[TBL] [Abstract] [Full Text] [Related]
7. Decoding dynamic interactions between EGFR-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
[TBL] [Abstract] [Full Text] [Related]
8. 5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in lung cancer.
Shao J; Xu Y; Olsen RJ; Kasparian S; Sun K; Mathur S; Zhang J; He C; Chen SH; Bernicker EH; Li Z
Cells; 2024 Apr; 13(8):. PubMed ID: 38667328
[TBL] [Abstract] [Full Text] [Related]
9. Codelivery of CPT and siPHB1 with GSH/ROS Dual-Responsive Hybrid Nanoparticles Based on a [12]aneN
Liang YX; Sun XY; Xu DZ; Gao YN; Tang Q; Lu ZL; Liu Y
ACS Appl Bio Mater; 2024 May; 7(5):3202-3214. PubMed ID: 38651918
[TBL] [Abstract] [Full Text] [Related]
10. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell lung cancer Treated with Immunotherapy.
Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
[TBL] [Abstract] [Full Text] [Related]
11. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Diseases and Injuries Collaborators
Lancet; 2024 May; 403(10440):2133-2161. PubMed ID: 38642570
[TBL] [Abstract] [Full Text] [Related]
12. Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.
Divan HA; Bittoni MA; Krishna A; Carbone DP
BMC Cancer; 2024 Apr; 24(1):424. PubMed ID: 38580900
[TBL] [Abstract] [Full Text] [Related]
13. A cross-sectional study of sleep disturbance among middle-aged cancer patients at Vietnam National cancer Hospital.
Pham AT; Do MT; Tran HTT
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2055. PubMed ID: 38577715
[TBL] [Abstract] [Full Text] [Related]
14. Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
Zeng A; Yin Y; Xu Z; Abuduwayiti A; Yang F; Shaik MS; Wang C; Chen K; Wang C; Fang X; Dai J
BMC Cancer; 2024 Mar; 24(1):396. PubMed ID: 38553708
[TBL] [Abstract] [Full Text] [Related]
15. Research autopsy programmes in oncology: shared experience from 14 centres across the world.
Geukens T; Maetens M; Hooper JE; Oesterreich S; Lee AV; Miller L; Atkinson JM; Rosenzweig M; Puhalla S; Thorne H; Devereux L; Bowtell D; Loi S; Bacon ER; Ihle K; Song M; Rodriguez-Rodriguez L; Welm AL; Gauchay L; Murali R; Chanda P; Karacay A; Naceur-Lombardelli C; Bridger H; Swanton C; Jamal-Hanjani M; Kollath L; True L; Morrissey C; Chambers M; Chinnaiyan AM; Wilson A; Mehra R; Reichert Z; Carey LA; Perou CM; Kelly E; Maeda D; Goto A; Kulka J; Székely B; Szasz AM; Tőkés AM; Van Den Bogaert W; Floris G; Desmedt C
J Pathol; 2024 Jun; 263(2):150-165. PubMed ID: 38551513
[TBL] [Abstract] [Full Text] [Related]
16. Outcomes of Patients with Non-Small Cell lung cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.
Nannini S; Guisier F; Curcio H; Ricordel C; Demontrond P; Abdallahoui S; Baloglu S; Greillier L; Chouaid C; Schott R
Curr Oncol; 2024 Mar; 31(3):1656-1666. PubMed ID: 38534959
[TBL] [Abstract] [Full Text] [Related]
17. A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.
Li LX; Socinski MA; Kichenadasse G; Karapetis CS; Shahnam A; McKinnon RA; Rowland A; Hopkins AM; Sorich MJ
BMC Cancer; 2024 Mar; 24(1):379. PubMed ID: 38528478
[TBL] [Abstract] [Full Text] [Related]
18. Tumor treating fields suppress tumor cell growth and neurologic decline in models of spinal metastases.
Ledbetter D; de Almeida RAA; Wu X; Naveh A; Patel CB; Gonzalez Q; Beckham TH; North R; Rhines L; Li J; Ghia A; Aten D; Tatsui C; Alvarez-Breckenridge C
JCI Insight; 2024 Mar; 9(9):. PubMed ID: 38512420
[TBL] [Abstract] [Full Text] [Related]
19. Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
Jung HA; Park B; Park S; Sun JM; Lee SH; Seok Ahn J; Ahn MJ
Lung Cancer; 2024 Apr; 190():107536. PubMed ID: 38493759
[TBL] [Abstract] [Full Text] [Related]
20. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract] [Full Text] [Related]
[Next]
